Impaired production of interleukin 6 and tumour necrosis factor α in whole blood cell cultures of patients with multiple myeloma

Cytokine

Volumn 10, Issue 12, 1998, Pages 993-996

  Filella, Xavier ^a   Bladé, Joan ^a   Montoto, Silvia ^a   Molina, Rafael ^a   Coca, Francisca ^a   Montserrat, Emili ^a   Ballesta, Antonio M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Cytokine; MGUS; Multiple myeloma; Tumour related immunosuppressive status

Indexed keywords

INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0032455001     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1998.0387     Document Type: Article

References (19)

1. 1. Whicher JT, Evans SW (1990) Cytokines in disease. Clin Chem 36:1269-1281.
2. 2. Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease in plasma cell dyscrasias. J Clin Invest 84:2008-2011.
3. 3. Solary E, Guignet M, Zeller V, Casasnovas RO, Caillot D, Chavanet P, Guy H, Mack G (1992) Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumor cell mass parameters in multiple myeloma. Am J Hematol 39:163-171.
4. 4. Filella X, Bladé J, López Guillermo A, Molina R, Rozman C, Ballesta AM (1996) Cytokines (IL-6, TNF-α, IL-1α) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev 20:52-56.
5. 5. Kawano M, Hirano T, Matsuda T, Taga T, Iwato K, Asaoku H, Tang B, Tanabe O, Tanka H, Kuramoto A, Kishimoto T (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332:83-86.
6. 6. Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, Lu ZY, Wijdenes J, Brochier J, Bataille R (1990) Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Net 1:193-201.
7. 7. Klein B, Bataille R (1992) Cytokine network in human multiple myeloma. Hematol/Oncol Clinics Am 6:273-284.
8. 8. Elsässer-Beile U, von Kleist S, Gallati H (1991). Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Methods 139:191-195.
9. 9. De Groote, Zangerle PF, Gevaert Y, Fasotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J, Gathy R, Lopez M, Dehart I, Igot D, Baudrihaye M, Delacroix, Franchimont P (1992). Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 4:239-248.
10. 10. Elssäser-Beile U, von Kleist S (1993) Cytokines as therapeutic and diagnostic agents. Tumor Biol 14:69-94.
11. 11. Zielinski CC, Mueller C, Tyl E, Tichatschek E, Kubista E, Spona J (1990) Impaired production of tumor necrosis factor in breast cancer. Cancer 66:1944-1948.
12. 12. Elssäser-Beile U, von Kleist S, Gallati H, Pfleiderer A (1991) Evaluation of cytokine levels in whole cell cultures of patients with gyneacological tumors as diagnostic parametres. Anticancer Res 11:1093-1096.
13. 13. Elssäser-Beile U, von Kleist S, Martin M (1992) Comparison of mitogen and virus induced interferon production in whole blood cell cultures of patients with various solid carcinomas and controls. Tumor Biol 13:358-363.
14. 14. Feinman R, Henriksen-DeStefano D, Tsujimoto M, Vilcek J (1987). Tumor necrosis factor is an important mediator of tumor cell killing by human monocytes. J Immunol 138:635-640.
15. 15. Luger T, Krutman J, Kirnbgauer A, Urbanski A, Schwarz T, Klappacher G, Kock A, Micksche M, Malejczyk J, Schauer E, May LT, Seghal PB (1989) IFN-β2/IL-6 augments the activity of human natural killer cells. J Immunol 143:1206-1209.
16. 16. Yamamura M, Modlin RL, Ohmen JD, Moy RL (1993). Local expression of antiinflammatory cytokines in cancer. J Clin Invest 91:1005-1010.
17. 17. Khar A, Kausalya S, Kamal MA (1996) AK-5 tumor-induced modulation of host immune function: Upregulation of TH-1-type cytokine response mediates early tumor regression. Cytokine Mol Ther 2:39-46.
18. 18. Chronic Leukemia-Myeloma Task Force : National Cancer Institute (1973) Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 4:145-158.
19. 19. Bladé J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL, Vives-Corrons JL, Montserrat E (1992) Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 81:391-394.